RFA released to support research projects with commercialization potential
A new RFA is available through the Translational Product Development Fund (TPDF) for projects that have the potential to be commercialized through the formation of a start-up company or execution of a license agreement with an established commercial entity.
“Technologies supported through this program have resulted in an impressive tech spin off, a project that is moving toward licensing, and another project that advanced closer to clinical trials,” said Tucker LeBien, PhD, Director of CTSI’s Office of Discovery and Translation, Senior Advisor for Research Operations, Office of Academic Clinical Affairs.
The TPDF program, a collaboration created in 2014 between CTSI, the Mayo Clinic Center for Clinical and Translational Science (CCaTS) and in conjunction with the Minnesota Partnership for Biotechnology and Medical Genomics, is in its sixth cycle.
Projects that include development of novel therapeutic compounds, devices, diagnostics, or IT products, are eligible to apply for Tier 1 funding of up to $50,000 in direct costs and project support to help advance it along the translational development pathway. Projects meeting initial milestones will be eligible to apply for additional funding through this program.
The program is open to all full-time University of Minnesota faculty at all campuses, and Mayo Clinic Associate Consultant to Consultant investigators from Mayo's Rochester campus. Researchers with joint projects between the two institutions are especially encouraged to apply.
Mandatory letters of intent are due 5pm, Wednesday, February 6 via an online form on CTSI’s website. Projects will be evaluated primarily on the basis of potential commercialization, readiness of the technology to advance to the next stage of translation from the proposed activity, and strength of the investigative team and any partners.